Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 6/20 | 0.42 |
| ▸ | RAB9A | P51151 | 3/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2464608 | 0.82 | GCK (0.41) | ALDH1A1 | |
| SCHEMBL190809 | 0.79 | GCK (0.62) | NPC1KCNH2NPSR1ALDH1A1SMN1; SMN2 | |
| SCHEMBL2522214 | 0.71 | NPC1 (1.00) | NPC1KCNH2NPSR1ALDH1A1CYP2C9 | |
| SCHEMBL17582498 | 0.71 | PLK1 (0.56) | NPC1NPSR1ALDH1A1EPHX1RAB9A | |
| SCHEMBL24092869 | 0.69 | EPHX1 (0.60) | NPC1KCNH2NPSR1ALDH1A1EPHX1 | |
| SCHEMBL31408209 | 0.69 | EPHX1 (0.60) | NPC1KCNH2NPSR1ALDH1A1EPHX1 | |
| SCHEMBL20489503 | 0.69 | NPC1 (0.77) | NPC1KCNH2NPSR1ALDH1A1SMN1; SMN2 | |
| SCHEMBL31167689 | 0.69 | NPC1 (0.72) | NPC1KCNH2NPSR1ALDH1A1SMN1; SMN2 | |
| SCHEMBL558304 | 0.69 | NPC1 (0.62) | NPC1KCNH2NPSR1ALDH1A1SMN1; SMN2 | |
| SCHEMBL1330239 | 0.69 | NPC1 (0.64) | NPC1KCNH2NPSR1ALDH1A1CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1986645-B1 | GLUCOKINASE ACTIVATORS | ARRAY BIOPHARMA INC (US) | 2012-01-04 | — | — | EP | disclosed |
| US-8022222-B2 | Glucokinase activators | ARRAY BIOPHARMA, INC. (US) | 2011-09-20 | — | — | US | disclosed |
| US-20090247526-A1 | GLUCOKINASE ACTIVATORS | ARRAY BIOPHARMA INC. (US) | 2009-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247526-A1 | GLUCOKINASE ACTIVATORS | GCKR, GCK, GALK1 | NPC1 1862/4885KCNH2 1689/4885NPSR1 4344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.